Phosphatidylinositol-3 kinase-Akt-mammalian target of rapamycin signaling pathway mediates contractility of human endometriotic stromal cells: A promising new target for the treatment of endometriosis-associated fibrosis  by Abe, Wakana et al.
lable at ScienceDirect
Gynecology and Minimally Invasive Therapy 3 (2014) 115e118Contents lists avaiGynecology and Minimally Invasive Therapy
journal homepage: www.e-gmit .comOriginal articlePhosphatidylinositol-3 kinase-Akt-mammalian target of rapamycin
signaling pathway mediates contractility of human endometriotic
stromal cells: A promising new target for the treatment of
endometriosis-associated ﬁbrosis
Wakana Abe a, Kaei Nasu a, b, *, Akitoshi Tsuno a, Yukie Kawano a, Hisashi Narahara a
a Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan
b Division of Obstetrics and Gynecology, Support System for Community Medicine, Faculty of Medicine, Oita University, Oita, Japana r t i c l e i n f o
Article history:
Received 8 March 2014
Received in revised form
11 July 2014
Accepted 11 July 2014
Available online 8 January 2015
Keywords:
Akt
contractility
endometriosis
mammalian target of rapamycin
phosphatidylinositol-3 kinaseConﬂicts of interest: All contributing authors declar
* Corresponding author. Department of Obstetrics
Medicine, Oita University, Idaigaoka 1-1, Hasama-ma
Japan.
E-mail address: nasu@oita-u.ac.jp (K. Nasu).
http://dx.doi.org/10.1016/j.gmit.2014.07.001
2213-3070/Copyright © 2015, The Asia-Paciﬁc Associationa b s t r a c t
Objective: To assess the involvement of phosphatidylinositol-3 kinase (PI3K)-Akt-mammalian target of
rapamycin (mTOR) on the extracellular matrix contractility of endometriotic cells.
Materials and methods: The effects of wortmannin, LY294002, Akt inhibitor IV, and Ku-0063794 on the
contractility of endometriotic cyst stromal cells (ECSCs) were investigated using collagen gel contraction
assay.
Results: All four inhibitors of PI3K-Akt-mTOR evaluated in the current study signiﬁcantly inhibited the
contractility of ECSCs.
Conclusion: The current ﬁndings suggest that the PI3K-Akt-mTOR signaling pathway is involved in the
development of endometriosis-associated ﬁbrosis. The PI3K-Akt-mTOR signaling pathway is a promising
target for the treatment of endometriosis.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Endometriosisda benign, estrogen-dependent, tumor-like dis-
ease characterized by chronic pelvic pain, dysmenorrhea, dyspar-
eunia, and/or subfertilitydis caused by the uncontrolled ectopic
growth of proliferative phase endometrial tissue. Women of repro-
ductive age are most commonly affected, with lesions usually occur-
ring in the peritoneum, ovaries, and rectovaginal septum.1 Symptoms
of endometriosis may markedly reduce a woman's quality of life.
Histologically, this disease is characterized by dense ﬁbrous
tissue surrounding the endometrial glands and stroma.2 During the
development and progression of endometriotic lesions, excess
ﬁbrosis typically leads to scarring, chronic pain, and/or alteration of
tissue function.2 Fibroblastic cells positive for a-smooth muscle
actin (SMA) are frequently detected in ﬁbrotic areas associatedwith
endometriosis of the peritoneum, ovary, rectovaginal septum, ande no conﬂicts of interest.
and Gynecology, Faculty of
chi, Yufu-shi, Oita 879-5593,
for Gynecologic Endoscopy and Minimuterosacral ligaments.2,3 Immunohistochemical analysis led Anaf
et al3 to suggest that endometriotic stromal cells can differentiate
into a-SMA-positive myoﬁbroblasts.
We have established a three-dimensional (3-D) collagen gel
culture system with human endometriotic cyst stromal cells
(ECSCs) as a model of ﬁbrosis formation in endometriosis.4e7 In this
system, ECSCs are cultured in ﬂoating collagen lattices to induce the
reorganization and compaction of collagen ﬁbers, resulting in the
contraction of collagen gels. This culture system provides a model
of mechanically relaxed tissue with low tensile strength compara-
ble to that in the early developmental stages of endometriotic le-
sions. Research on endometriotic stromal cell biology in 3-D
collagen matrices offers new opportunities to gain a better under-
standing of the reciprocal and adaptive interactions that take place
between cells and the surrounding matrix in a tissue-like envi-
ronment. Such interactions are integral to the regulation of endo-
metriotic tissue morphogenesis and the dynamics that characterize
endometriosis-associated ﬁbrosis.4e7
The phosphatidylinositol-3 kinase (PI3K)-Akt-mammalian
target of rapamycin (mTOR) pathway is a key cellular signaling
pathway that affects multiple cellular functions, including meta-
bolism, growth, proliferation, and apoptosis.8e10 The PI3K-Akt-ally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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including antigen receptors, cytokine receptors, vascular endothe-
lial growth factor receptors, and platelet-derived growth factor
receptors, epidermal growth factor receptor, human epidermal
growth factor receptor 2, insulin receptor, or the insulin-like
growth factor I receptor.11,12 Following the activation of receptor
tyrosine kinases, class IA PI3K phosphorylates phosphatidylinositol
4,5-bisphosphate (PIP2) generates phosphatidy
linositol-3,4,5-trisphosphate (PIP3) as a second messenger to re-
cruit and activate downstream targets, including Akt and PDK1
(phosphoinositide-dependent kinase-1), and then mTOR.13 mTOR
controls protein synthesis through phosphorylation and inactiva-
tion of the repressor of messenger RNA translation, eukaryotic
initiation factor 4E-binding protein 1, and through phosphorylation
and activation of S6 kinase.14
In the current study, we investigated the effects of PI3K-Akt-
mTOR inhibitors on the contractility of ECSCs. We also discuss a
novel therapeutic strategy for endometriosis-associated ﬁbrosis.
Materials and methods
ECSC isolation procedure and cell culture conditions
Endometriotic tissues were obtained from premenopausal pa-
tients in the mid- to late-proliferative phase who had undergone
salpingo-oophorectomy or cystectomy for ovarian endometriotic
cysts (n¼ 6, aged 27e32 years). None of the patients had undergone
any hormonal treatments for at least 12 months prior to the oper-
ation. This study was approved by the Institutional Review Board of
the Faculty of Medicine at Oita University, Oita, Japan. ECSCs were
isolated from ovarian endometriotic tissues by enzymatic digestion
as previously described.4 Isolated ECSCs were cultured in Dulbecco
modiﬁed eagle medium supplemented with 100 IU/mL of penicillin
(Gibco-BRL, Gaithersburg, MD, USA), 50 mg/mL of streptomycin
(Gibco-BRL), and 10% heat-inactivated charcoal-stripped fetal
bovine serum (FBS) (Gibco-BRL) at 37C in 5% CO2 in air.
After the third passage, the ECSCs in themonolayer culture were
>99% pure, as determined by immunocytochemical staining with
antibodies to vimentin (V9; Dako, Copenhagen, Denmark), CD10
(SS2/36; Dako), cytokeratin (Dako), factor VIII (Dako), and leuko-
cyte common antigen (2B11 þ PD7/26; Dako). These ECSCs were
used for the subsequent experiments.4 Each experiment was per-
formed in triplicate and repeated at least three times.
Collagen gel contraction assay
To assess the involvement of the PI3K-Akt-mTOR pathway on
the contractility of ECSCs, cellular collagen gel contraction assays
were performed as previously described.4,6 Wortmannin and
LY294002 were chosen as representative PI3K inhibitors, Akt in-
hibitor IV as a representative Akt inhibitor, and Ku-0063794 as a
representative mTOR inhibitor.
A sterile solution of acid-soluble collagen type I puriﬁed from
porcine tendons (Cellmatrix type I-A; Nitta Gelatin Inc., Osaka,
Japan) was prepared according to the manufacturer's instructions.
ECSCs were embedded in collagen gel and cultured three-
dimensionally. Brieﬂy, the ECSCs were suspended in collagen so-
lution (3.0  105 cells/mL), and this collagen/cell mixture (2 mL/
plate) was dispensed into 35-mm culture plates (Corning, Corning
Incorporated, Corning, NY, U.S.A) coated with 0.2% BSA (bovine
serum albumin), after which the mixture was allowed to poly-
merize at 37C for 30 minutes. Immediately after polymerization,
1 mL of culture medium containing wortmannin (ﬁnal concentra-
tion: 1mM), LY294002 (ﬁnal concentration: 50mM), Akt inhibitor IV
(ﬁnal concentration: 25mM), or Ku-0063794 (ﬁnal concentration:10mM) was added to each plate. All of these PI3K-Akt-mTOR in-
hibitors were purchased from Merck (Darmstadt, Germany). After
incubation for 48 hours, the collagen gels were photographed, and
the area of the gel surface was measured using the public domain
image program ImageJ 1.44 developed at the National Institutes of
Health (Bethesda, MD, USA).
Statistical analysis
The gel surface area at 0 hours that is equal to the surface area of
the 35-mm culture plate was deﬁned as 100%, which is equal to the
surface area of the 35-mm culture dish. Data were calculated as
percentages relative to the untreated controls at 0 hours, presented
as means ± standard deviations, and appropriately analyzed using
the t test with Bonferroni correction using Sigmaplot 11.2 (Systat
Software, Inc., San Jose, CA, USA). Values of p < 0.05 were consid-
ered to be statistically signiﬁcant.
Results
The effect of inhibitors of the PI3K-Akt-mTOR pathway on the
contractility of ECSCs was evaluated using a collagen gel contrac-
tion assay. As shown in Fig. 1, in the presence of 10% FBS, untreated
ECSCs showed signiﬁcant collagen gel contractility after 48 hours of
3-D culture (relative surface areawas 19.8± 2.6%). The contractility
of ECSCs was signiﬁcantly attenuated by the addition of wort-
mannin (1mM), LY294002 (mM), Akt inhibitor IV (mM), and Ku-
0063794 (10mM) (p < 0.0001).
Discussion
In an effort to clarify the pathological ﬁbrosis in endometriosis
and to establish novel therapeutic strategies for this disease, our
laboratory has been conducting an ongoing investigation into the
contractile proﬁles of endometriotic cells. In the current study, we
demonstrated that the inhibitors of the PI3K-Akt-mTOR pathway
signiﬁcantly attenuated the contractility of ECSCs in vitro. This
ﬁnding suggests that the PI3K-Akt-mTOR signaling pathway is
involved in the pathogenesis of endometriosis-associated ﬁbrosis.
It also suggests that the PI3K-Akt-mTOR signaling pathway could
serve as a target for the treatment and prevention of
endometriosis-associated ﬁbrosis.
The PI3K-Akt-mTOR signaling pathway has been found to be
activated in ovarian endometriosis.15e17 Akt activity is higher in
ovarian endometriosis than in the normal endometrium,15 and it
has been postulated that estrogens might be one of the factors
responsible for the high Akt activation in endometriotic cells.17
Leconte et al18 found that Akt is hyperactivated in endometriotic
lesions from patients with deep inﬁltrative endometriosis, as in
ovarian endometriosis; however, ERK (extracellular signal-regu-
lated kinase) and Akt activation predominates in endometriotic
stromal cells in deep inﬁltrative endometriosis. Leconte et al18 also
suggested that the constitutive activation of the AKT pathway in
endometriotic cells could be explained by the overproduction of
endogenous ROS (reactive oxygen species). Similarly, Laschke
et al19 reported that rapamycin induced the regression of endo-
metriosis by inhibiting neovascularization and cell proliferation.
Various phosphoproteins that interact with the PI3K-Akt-mTOR
pathway show increased expression in a subtype-speciﬁc manner,
which might lead to the development of endometriosis. Expression
proﬁling of genes involved in the PI3K-Akt-mTOR pathway has
shown high expression and/or activation of phosphatase and tensin
homolog deleted from chromosome 10 (PTEN),20 p21-activated
kinase (PAK1),21 X chromosome-linked IAP (inhibitor of apoptosis
protein) (XIAP),22 and NFkB123,24 in endometriosis.
Fig. 1. Effects of PI3K-Akt-mTOR inhibitors on the contractility of endometriotic cyst stromal cells (ECSCs) as assessed by collagen gel contraction assay. ECSCs were cultured in
three-dimensional collagen gels for 48 hours in the presence of wortmannin (1mM), LY294002 (50mM), Akt inhibitor IV (25mM), or Ku-0063794 (10mM). (A) Photograph of the
collagen gels. The ECSC-mediated collagen gel contraction was assessed by measuring the gel surface area using an image analysis program. The contractility of untreated ECSCs at
0 hours that is equal to the surface area of a 35-mm culture plate was deﬁned as 100%. (B) The relative gel surface areas of the ECSCs treated with PI3K-Akt-mTOR inhibitors were
calculated. Data are presented as means ± standard deviations of representative experiments. *p < 0.0001 versus untreated controls (Bonferroni test). PI3K-Akt-
mTOR ¼ phosphatidylinositol-3 kinase -Akt-mammalian target of rapamycin.
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important role in activation of focal adhesion kinase and a-SMA
and stress ﬁber formation.25 Recently, Leconte et al18 demonstrated
that Akt-mTOR inhibition by temsirolimus decreasedendometriotic cell proliferation both in vitro and in a mouse model
of deep inﬁltrating endometriosis. Rapamycin (sirolimus) is a bac-
terial macrolide, which is currently widely used as an antifungal,
immunosuppressant, and antitumor drug that blocks mTOR.26
W. Abe et al. / Gynecology and Minimally Invasive Therapy 3 (2014) 115e118118After forming a complex with the FK506 binding protein-12,
rapamycin blocks mTOR, which is known to be a central
controller of multiple mitogenic signaling pathways, regulating cell
growth under physiological and pathological conditions.27 The
mTOR pathway drives a feedback loop and keeps the PI3K/Akt ac-
tivity under tight control. One consequence of mTOR inhibition is
alleviation of this negative feedback loop, resulting in activation of
PI3K and subsequent activation of Akt. Therefore, simultaneous
targeting of both PI3K/Akt and mTOR has the potential to inhibit
both upstream and downstream signaling in the pathway. Dual
PI3K/mTOR inhibitors are now under preclinical evaluation.28
It has been suggested that the mevalonate-Rho/ROCK pathway
plays important roles in the formation of endometriosis-associated
ﬁbrosis. We previously demonstrated that simvastatin, which acts
as a Rho inhibitor by inhibiting 3-hydroxy-3-methylglutary
lcoenzyme A reductase, and fasudil and Y27632, representative
ROCK (Rho-associated coiled-coil-forming protein kinase) in-
hibitors in clinical and preclinical use, reduced the proliferation and
contractility of ECSCs.4,6 The PI3K-Akt-mTOR signaling pathway
should be recognized as an additional regulatory mechanism of
endometriosis-associated ﬁbrosis in addition to the mevalonate-
Rho/ROCK pathway. It is also speculated that targeting of the
PI3K-Akt-mTOR signaling pathway offers new prospects for the
treatment and prevention of endometriosis-associated ﬁbrosis.Acknowledgments
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